MAP2K7 and breast cancer: The GDSC database was also used to observe the IC50 of three MEK inhibitors (trametinib, selumetinib, and refametinib) in various subtypes of breast cancer, and CLBC was sensitive to three MEK inhibitors compared with other subtypes.